References
Abbaspour Kasgari, H., Moradi, S., Shabani, A.M., Babamahmoodi, F.,
Davoudi Badabi, A.R., Davoudi, L., et al. (2020). Evaluation of the
efficacy of sofosbuvir plus daclatasvir in combination with ribavirin
for hospitalized COVID-19 patients with moderate disease compared with
standard care: a single-centre, randomized controlled trial. J.
Antimicrob. Chemother. 75 : 3373–3378.
Abu Esba, L.C., Alqahtani, R.A., Thomas, A., Shamas, N., Alswaidan, L.,
and Mardawi, G. (2020). Ibuprofen and NSAID Use in COVID-19 Infected
Patients Is Not Associated with Worse Outcomes: A Prospective Cohort
Study. Infect. Dis. Ther. 1–16.
Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan, T.P.,
Lu, X., et al. (2018). Coronavirus susceptibility to the antiviral
remdesivir (GS-5734) is mediated by the viral polymerase and the
proofreading exoribonuclease. MBio 9 :.
Ali, N. (2020). Role of vitamin D in preventing of COVID-19 infection,
progression and severity. J. Infect. Public Health 13 :
1373–1380.
Alshaeri, H.K., and Natto, Z.S. (2020). A contemporary look at COVID-19
medications: Available and potentially effective drugs. Eur. Rev. Med.
Pharmacol. Sci. 24 : 9188–9195.
American Association for Clinical Chemistry (2020). Disseminated
Intravascular Coagulation in COVID-19—Insights From the Front Lines
| AACC.org.
American Society of Hematology (2020a). COVID-19 and Coagulopathy -
Hematology.org.
American Society of Hematology (2020b). COVID-19 and VTE-Anticoagulation
- Hematology.org.
Angus, D.C., Derde, L., Al-Beidh, F., Annane, D., Arabi, Y., Beane, A.,
et al. (2020). Effect of Hydrocortisone on Mortality and Organ Support
in Patients with Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid
Domain Randomized Clinical Trial. JAMA - J. Am. Med. Assoc. 324 :
1317–1329.
Annane, D., Heming, N., Grimaldi-Bensouda, L., Frémeaux-Bacchi, V.,
Vigan, M., Roux, A.L., et al. (2020). Eculizumab as an emergency
treatment for adult patients with severe COVID-19 in the intensive care
unit: A proof-of-concept study. EClinicalMedicine 28 : 100590.
ANSM (2019). Anti-inflammatoires non stéroïdiens (AINS) et complications
infectieuses graves - Point d’Information actualisé le 20/05/2020 -
ANSM : Agence nationale de sécurité du médicament et des produits de
santé.
Arabi, Y.M., Hajeer, A.H., Luke, T., Raviprakash, K., Balkhy, H.,
Johani, S., et al. (2016). Feasibility of using convalescent plasma
immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg. Infect. Dis.22 : 1554–1561.
Asakura, H., and Ogawa, H. (2020). COVID-19-associated coagulopathy and
disseminated intravascular coagulation. Int. J. Hematol. 1 : 3.
AstraZeneca (2020). AstraZeneca’s COVID-19 vaccine authorised for
emergency supply in the UK.
Atallah, B., Mallah, S.I., and AlMahmeed, W. (2020). Anticoagulation in
COVID-19. Eur. Hear. J. - Cardiovasc. Pharmacother. 6 : 260–261.
Ayerbe, L., Risco, C., and Ayis, S. (2020). The association between
treatment with heparin and survival in patients with Covid-19. J.
Thromb. Thrombolysis 50 : 298–301.
Baden, L.R., Sahly, H.M. El, Essink, B., Kotloff, K., Frey, S., Novak,
R., et al. (2020). Efficacy and Safety of the mRNA-1273 SARS-CoV-2
Vaccine. N. Engl. J. Med. NEJMoa2035389.
Bairi, K. El, Trapani, D., Petrillo, A., Page, C. Le, Zbakh, H.,
Daniele, B., et al. (2020). Repurposing anticancer drugs for the
management of COVID-19. Eur. J. Cancer 141 : 40–61.
Bancos, S., Bernard, M.P., Topham, D.J., and Phipps, R.P. (2009).
Ibuprofen and other widely used non-steroidal anti-inflammatory drugs
inhibit antibody production in human cells. Cell. Immunol. 258 :
18–28.
Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S.,
Kalil, A.C., et al. (2020). Remdesivir for the Treatment of Covid-19 —
Final Report. N. Engl. J. Med.
Benucci, M., Giannasi, G., Cecchini, P., Gobbi, F.L., Damiani, A.,
Grossi, V., et al. (2020). COVID‐19 pneumonia treated with Sarilumab: A
clinical series of eight patients. J. Med. Virol. 92 : 2368–2370.
Bhattacharyya, A., Kumar, S., Sarma, P., Kaur, H., Prajapat, M.,
Shekhar, N., et al. (2020). Safety and efficacy of lopinavir/ ritonavir
combination in COVID-19: A systematic review, meta-analysis, and
meta-regression analysis. Indian J. Pharmacol. 52 : 313–323.
Bian, H., Zheng, Z.-H., Wei, D., Zhang, Z., Kang, W.-Z., Hao, C.-Q., et
al. (2020). Meplazumab treats COVID-19 pneumonia: an open-labelled,
concurrent controlled add-on clinical trial. MedRxiv
2020.03.21.20040691.
Bianconi, V., Violi, F., Fallarino, F., Pignatelli, P., Sahebkar, A.,
and Pirro, M. (2020). Is Acetylsalicylic Acid a Safe and Potentially
Useful Choice for Adult Patients with COVID-19 ? Drugs 80 :
1383–1396.
Bloch, E.M., Shoham, S., Casadevall, A., Sachais, B.S., Shaz, B.,
Winters, J.L., et al. (2020). Deployment of convalescent plasma for the
prevention and treatment of COVID-19. J. Clin. Invest. 130 :
2757–2765.
Boulware, D.R., Pullen, M.F., Bangdiwala, A.S., Pastick, K.A., Lofgren,
S.M., Okafor, E.C., et al. (2020). A Randomized Trial of
Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N. Engl. J.
Med. 383 : 517–525.
Boyle, A.J., Gangi, S. Di, Hamid, U.I., Mottram, L.J., McNamee, L.,
White, G., et al. (2015). Aspirin therapy in patients with acute
respiratory distress syndrome (ARDS) is associated with reduced
intensive care unit mortality: A prospective analysis. Crit. Care19 :.
Bruce, E., Barlow-Pay, F., Short, R., Vilches-Moraga, A., Price, A.,
McGovern, A., et al. (2020). Prior Routine Use of Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised
Patients with COVID-19. J. Clin. Med. 9 : 2586.
Buijsers, B., Yanginlar, C., Maciej-Hulme, M.L., Mast, Q. de, and Vlag,
J. van der (2020). Beneficial non-anticoagulant mechanisms underlying
heparin treatment of COVID-19 patients. EBioMedicine 59 : 102969.
Cacciapuoti, S., Rosa, A. De, Gelzo, M., Megna, M., Raia, M., Pinchera,
B., et al. (2020). Immunocytometric analysis of COVID patients: A
contribution to personalized therapy? Life Sci. 261 : 118355.
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., et al. (2020).
Experimental Treatment with Favipiravir for COVID-19: An Open-Label
Control Study. Engineering.
Caly, L., Druce, J.D., Catton, M.G., Jans, D.A., and Wagstaff, K.M.
(2020). The FDA-approved drug ivermectin inhibits the replication of
SARS-CoV-2 in vitro. Antiviral Res. 178 :.
Camprubí, D., Almuedo-Riera, A., Martí-Soler, H., Soriano, A., Hurtado,
J.C., Subirà, C., et al. (2020). Lack of efficacy of standard doses of
ivermectin in severe COVID-19 patients. PLoS One 15 : e0242184.
Cantini, F., Niccoli, L., Matarrese, D., Nicastri, E., Stobbione, P.,
and Goletti, D. (2020a). Baricitinib therapy in COVID-19: A pilot study
on safety and clinical impact. J. Infect. 81 : 318–356.
Cantini, F., Niccoli, L., Nannini, C., Matarrese, D., Natale, M.E. Di,
Lotti, P., et al. (2020b). Beneficial impact of Baricitinib in COVID-19
moderate pneumonia; multicentre study. J. Infect. 81 : 647–679.
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., et al. (2020). A
Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe
Covid-19. N. Engl. J. Med. 382 : 1787–1799.
Capoluongo, E.D., Amato, F., and Castaldo, G. (2020). The friendly use
of chloroquine in the COVID-19 disease: A warning for the G6PD-deficient
males and for the unaware carriers of pathogenic alterations of the G6PD
gene. Clin. Chem. Lab. Med. 58 : 1162–1164.
Capuano, A., Rossi, F., and Paolisso, G. (2020a). Covid-19 Kills More
Men Than Women: An Overview of Possible Reasons. Front. Cardiovasc. Med.7 : 131.
Capuano, A., Scavone, C., Racagni, G., and Scaglione, F. (2020b). NSAIDs
in patients with viral infections, including Covid-19: Victims or
perpetrators? Pharmacol. Res. 157 : 104849.
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., et al.
(2020a). Favipiravir versus Arbidol for COVID-19: A Randomized Clinical
Trial.
CHEN, J., LIU, D., LIU, L., LIU, P., XU, Q., XIA, L., et al. (2020). A
pilot study of hydroxychloroquine in treatment of patients with common
coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci) 49 :
1–10.
Chen, J., Xia, L., Liu, L., Xu, Q., Ling, Y., Huang, D., et al. (2020b).
Antiviral activity and safety of darunavir/Cobicistat for the treatment
of COVID-19. Open Forum Infect. Dis. 7 :.
Chen, P., Nirula, A., Heller, B., Gottlieb, R.L., Boscia, J., Morris,
J., et al. (2020c). SARS-CoV-2 Neutralizing Antibody LY-CoV555 in
Outpatients with Covid-19. N. Engl. J. Med.
Chen, W., Janz, D.R., Bastarache, J.A., May, A.K., O’Neal, H.R.,
Bernard, G.R., et al. (2015). Prehospital aspirin use is associated with
reduced risk of acute respiratory distress syndrome in critically ill
patients: A propensity-adjusted analysis. Crit. Care Med. 43 :
801–807.
Cheng, Y., Wong, R., Soo, Y.O.Y., Wong, W.S., Lee, C.K., Ng, M.H.L., et
al. (2005). Use of convalescent plasma therapy in SARS patients in Hong
Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24 : 44–46.
Choi, M.J., Kang, M., Shin, S.Y., Noh, J.Y., Cheong, H.J., Kim, W.J., et
al. (2020). Comparison of antiviral effect for mild-to-moderate COVID-19
cases between lopinavir/ritonavir versus hydroxychloroquine: A
nationwide propensity score-matched cohort study. Int. J. Infect. Dis.
Chow, J.H., Khanna, A.K., Kethireddy, S., Yamane, D., Levine, A.,
Jackson, A.M., et al. (2020). Aspirin Use is Associated with Decreased
Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in
Hospitalized Patients with COVID-19. Anesth. Analg. Publish Ah :
Cingolani, A., Tummolo, A.M., Montemurro, G., Gremese, E., Larosa, L.,
Cipriani, M.C., et al. (2020). Baricitinib as rescue therapy in a
patient with COVID-19 with no complete response to sarilumab. Infection48 : 767–771.
Cordon-Cardo, C., Pujadas, E., Wajnberg, A., Sebra, R., Patel, G.,
Firpo-Betancourt, A., et al. (2020). COVID-19: Staging of a New Disease.
Cancer Cell 38 : 594–597.
D’avolio, A., Avataneo, V., Manca, A., Cusato, J., Nicolò, A. De,
Lucchini, R., et al. (2020). 25-hydroxyvitamin D concentrations are
lower in patients with positive PCR for SARS-CoV-2. Nutrients12 :.
Deeks, E.D. (2018). Darunavir/Cobicistat/Emtricitabine/Tenofovir
Alafenamide: A Review in HIV-1 Infection. Drugs 78 : 1013–1024.
Deng, L., Li, C., Zeng, Q., Liu, X., Li, X., Zhang, H., et al. (2020).
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus
Disease 2019: A retrospective cohort study. J. Infect. 81 :
e1–e5.
Dequin, P.F., Heming, N., Meziani, F., Plantefève, G., Voiriot, G.,
Badié, J., et al. (2020). Effect of Hydrocortisone on 21-Day Mortality
or Respiratory Support among Critically Ill Patients with COVID-19: A
Randomized Clinical Trial. JAMA - J. Am. Med. Assoc. 324 :
1298–1306.
Doi, K., Ikeda, M., Hayase, N., Moriya, K., Morimura, N., Maehara, H.,
et al. (2020). Nafamostat mesylate treatment in combination with
favipiravir for patients critically ill with Covid-19: a case series.
Crit. Care 24 :.
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., et al. (2020).
Effectiveness of convalescent plasma therapy in severe COVID-19
patients. Proc. Natl. Acad. Sci. U. S. A. 117 : 9490–9496.
Eli Lilly and Company Lilly’s neutralizing antibody bamlanivimab
(LY-CoV555) receives interim authorization from Health Canada as a
treatment for COVID-19 | Eli Lilly and Company.
Elsawah, H.K., Elsokary, M.A., Abdallah, M.S., and ElShafie, A.H.
(2020). Efficacy and safety of remdesivir in hospitalized Covid‐19
patients: Systematic review and meta‐analysis including network
meta‐analysis. Rev. Med. Virol.
Erlich, J.M., Talmor, D.S., Cartin-Ceba, R., Gajic, O., and Kor, D.J.
(2011). Prehospitalization antiplatelet therapy is associated with a
reduced incidence of acute lung injury: A population-based cohort study.
Chest 139 : 289–295.
Eslami, G., Mousaviasl, S., Radmanesh, E., Jelvay, S., Bitaraf, S.,
Simmons, B., et al. (2020). The impact of sofosbuvir/daclatasvir or
ribavirin in patients with severe COVID-19. J. Antimicrob. Chemother.75 : 3366–3372.
European Medicine agency (2020). COVID-19: chloroquine and
hydroxychloroquine only to be used in clinical trials or emergency use
programmes | European Medicines Agency.
European Medicine Agency Update on remdesivir - EMA will evaluate new
data from Solidarity trial | European Medicines Agency.
European Medicine Agency (2020a). COVID-19: reminder of risk of serious
side effects with chloroquine and hydroxychloroquine.
European Medicine Agency (2020b). COVID-19: reminder of the risks of
chloroquine and hydroxychloroquine | European Medicines Agency.
European Medicine Agency (2020c). EMA endorses use of dexamethasone in
COVID-19 patients on oxygen or mechanical ventilation |
European Medicines Agency.
European Medicine Agency (2020d). Meeting highlights from the
Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 November 2020
| European Medicines Agency.
Favalli, E.G., Biggioggero, M., Maioli, G., and Caporali, R. (2020).
Baricitinib for COVID-19: a suitable treatment? Lancet Infect. Dis.20 : 1012–1013.
Fehr, A.R., and Perlman, S. (2015). Coronaviruses: An overview of their
replication and pathogenesis. In Coronaviruses: Methods and Protocols,
(Springer New York), pp 1–23.
Ferrara, N., Hillan, K.J., and Novotny, W. (2005). Bevacizumab
(Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Biochem. Biophys. Res. Commun. 333 : 328–335.
Food and Drug Administration Coronavirus (COVID-19) Update: FDA
Authorizes Monoclonal Antibodies for Treatment of COVID-19 |
FDA.
Gao, G., Wang, A., Wang, S., Qian, F., Chen, M., Yu, F., et al. (2020).
Brief Report: Retrospective Evaluation on the Efficacy of
Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19
Patients. J. Acquir. Immune Defic. Syndr. 85 : 239–243.
Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe,
M., et al. (2020). Hydroxychloroquine and azithromycin as a treatment of
COVID-19: results of an open-label non-randomized clinical trial. Int.
J. Antimicrob. Agents 56 : 105949.
Goldman, J.D., Lye, D.C.B., Hui, D.S., Marks, K.M., Bruno, R.,
Montejano, R., et al. (2020). Remdesivir for 5 or 10 Days in Patients
with Severe Covid-19. N. Engl. J. Med.
Gozzo, L., Viale, P., Longo, L., Vitale, D.C., and Drago, F. (2020). The
Potential Role of Heparin in Patients With COVID-19: Beyond the
Anticoagulant Effect. A Review. Front. Pharmacol. 11 :.
Gralinski, L.E., Sheahan, T.P., Morrison, T.E., Menachery, V.D., Jensen,
K., Leist, S.R., et al. (2018). Complement activation contributes to
severe acute respiratory syndrome coronavirus pathogenesis. MBio9 :.
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A.,
et al. (2020). Compassionate Use of Remdesivir for Patients with Severe
Covid-19. N. Engl. J. Med. 382 : 2327–2336.
Gremese, E., Cingolani, A., Bosello, S.L., Alivernini, S., Tolusso, B.,
Perniola, S., et al. (2020). Sarilumab use in severe SARS-CoV-2
pneumonia. EClinicalMedicine 27 :.
Guo, Y.R., Cao, Q.D., Hong, Z.S., Tan, Y.Y., Chen, S.D., Jin, H.J., et
al. (2020a). The origin, transmission and clinical therapies on
coronavirus disease 2019 (COVID-19) outbreak- A n update on the status.
Mil. Med. Res. 7 :.
Guo, Y.R., Cao, Q.D., Hong, Z.S., Tan, Y.Y., Chen, S.D., Jin, H.J., et
al. (2020b). The origin, transmission and clinical therapies on
coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
Mil. Med. Res. 7 : 11.
Hastie, C.E., Mackay, D.F., Ho, F., Celis-Morales, C.A., Katikireddi,
S.V., Niedzwiedz, C.L., et al. (2020). Vitamin D concentrations and
COVID-19 infection in UK Biobank. Diabetes Metab. Syndr. Clin. Res. Rev.14 : 561–565.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T.,
Erichsen, S., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and
TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell181 : 271-280.e8.
Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell,
L., et al. (2020a). Dexamethasone in Hospitalized Patients with Covid-19
— Preliminary Report. N. Engl. J. Med.
Horby, P.W., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Emberson,
J., et al. (2020b). Lopinavir–ritonavir in patients admitted to
hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label,
platform trial. Lancet 396 : 1345–1352.
Huang, M., Tang, T., Pang, P., Li, M., Ma, R., Lu, J., et al. (2020).
Treating COVID-19 with Chloroquine. J. Mol. Cell Biol. 12 :
322–325.
Hung, I.F.N., Lung, K.C., Tso, E.Y.K., Liu, R., Chung, T.W.H., Chu,
M.Y., et al. (2020). Triple combination of interferon beta-1b,
lopinavir–ritonavir, and ribavirin in the treatment of patients
admitted to hospital with COVID-19: an open-label, randomised, phase 2
trial. Lancet 395 : 1695–1704.
Italian Medicine Agency RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO.
Italian Medicine Agency (2020a). COVID-19: STUDIO RANDOMIZZATO ITALIANO,
NESSUN BENEFICIO DAL TOCILIZUMAB.
Italian Medicine Agency (2020b). Idrossiclorochina nella terapia dei
pazienti adulti con COVID-19 .
Ivashchenko, A.A., Dmitriev, K.A., Vostokova, N. V, Azarova, V.N.,
Blinow, A.A., Egorova, A.N., et al. (2020). AVIFAVIR for Treatment of
Patients with Moderate COVID-19: Interim Results of a Phase II/III
Multicenter Randomized Clinical Trial. Clin. Infect. Dis.
Iwasaka, S., Shono, Y., Tokuda, K., Nakashima, K., Yamamoto, Y., Maki,
J., et al. (2020). Clinical improvement in a patient with severe
coronavirus disease 2019 after administration of hydroxychloroquine and
continuous hemodiafiltlation with nafamostat mesylate. J. Infect.
Chemother. 26 : 1319–1323.
Janssen (2020). Janssen begins second Phase III Covid-19 vaccine trial .
Jeronimo, C.M.P., Farias, M.E.L., Val, F.F.A., Sampaio, V.S., Alexandre,
M.A.A., Melo, G.C., et al. (2020). Methylprednisolone as Adjunctive
Therapy for Patients Hospitalized With Coronavirus Disease 2019
(COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb,
Placebo-controlled Trial. Clin. Infect. Dis.
Jovic, T.H., Ali, S.R., Ibrahim, N., Jessop, Z.M., Tarassoli, S.P.,
Dobbs, T.D., et al. (2020). Could vitamins help in the fight against
covid-19? Nutrients 12 : 1–30.
Karolyi, M., Pawelka, E., Mader, T., Omid, S., Kelani, H., Ely, S., et
al. (2020). Hydroxychloroquine versus lopinavir/ritonavir in severe
COVID-19 patients: Results from a real-life patient cohort. Wien. Klin.
Wochenschr.
Khamis, F., Naabi, H. Al, Lawati, A. Al, Ambusaidi, Z., Sharji, M. Al,
Barwani, U. Al, et al. (2020). Randomized Controlled Open Label Trial on
the Use of Favipiravir Combined with Inhaled Interferon beta-1b in
Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia. Int.
J. Infect. Dis.
Kim, E.J., Choi, S.H., Park, J.S., Kwon, Y.S., Lee, J., Kim, Y., et al.
(2020). Use of darunavir-cobicistat as a treatment option for critically
ill patients with sars-cov-2 infection. Yonsei Med. J. 61 :
826–830.
Klok, F.A., Kruip, M.J.H.A., Meer, N.J.M. van der, Arbous, M.S.,
Gommers, D.A.M.P.J., Kant, K.M., et al. (2020). Incidence of thrombotic
complications in critically ill ICU patients with COVID-19. Thromb. Res.191 : 145–147.
Kor, D.J., Carter, R.E., Park, P.K., Festic, E., Banner-Goodspeed, V.M.,
Hinds, R., et al. (2016). Effect of aspirin on development of ARDS in
at-risk patients presenting to the emergency department the LIPS-a
randomized clinical trial. JAMA - J. Am. Med. Assoc. 315 :
2406–2414.
Kor, D.J., Erlich, J., Gong, M.N., Malinchoc, M., Carter, R.E., Gajic,
O., et al. (2011). Association of prehospitalization aspirin therapy and
acute lung injury: Results of a multicenter international observational
study of at-risk patients. Crit. Care Med. 39 : 2393–2400.
Kraft, C.S., Hewlett, A.L., Koepsell, S., Winkler, A.M., Kratochvil,
C.J., Larson, L., et al. (2015). The Use of TKM-100802 and Convalescent
Plasma in 2 Patients With Ebola Virus Disease in the United States.
Clin. Infect. Dis. 61 : 496–502.
Laurence, J., Mulvey, J.J., Seshadri, M., Racanelli, A., Harp, J.,
Schenck, E.J., et al. (2020). Anti-complement C5 therapy with eculizumab
in three cases of critical COVID-19. Clin. Immunol. 219 :.
Lecronier, M., Beurton, A., Burrel, S., Haudebourg, L., Deleris, R.,
Marec, J. Le, et al. (2020). Comparison of hydroxychloroquine,
lopinavir/ritonavir, and standard of care in critically ill patients
with SARS-CoV-2 pneumonia: An opportunistic retrospective analysis.
Crit. Care 24 :.
Leppkes, M., Knopf, J., Naschberger, E., Lindemann, A., Singh, J.,
Herrmann, I., et al. (2020). Vascular occlusion by neutrophil
extracellular traps in COVID-19. EBioMedicine 58 :.
Leuchte, H.H., Baezner, C., Baumgartner, R.A., Bevec, D., Bacher, G.,
Neurohr, C., et al. (2008). Inhalation of vasoactive intestinal peptide
in pulmonary hypertension. Eur. Respir. J. 32 : 1289–1294.
Levi, M., Thachil, J., Iba, T., and Levy, J.H. (2020). Coagulation
abnormalities and thrombosis in patients with COVID-19. Lancet Haematol.7 : e438–e440.
Lewis, T.C., Adhikari, S., Tatapudi, V., Holub, M., Kunichoff, D.,
Troxel, A.B., et al. (2020). A Propensity-Matched Cohort Study of
Tocilizumab in Patients With Coronavirus Disease 2019. Crit. Care
Explor. 2 : e0283.
Li, H., Liu, L., Zhang, D., Xu, J., Dai, H., Tang, N., et al. (2020a).
SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet395 : 1517–1520.
Li, L., Zhang, W., Hu, Y., Tong, X., Zheng, S., Yang, J., et al.
(2020b). Effect of Convalescent Plasma Therapy on Time to Clinical
Improvement in Patients with Severe and Life-threatening COVID-19: A
Randomized Clinical Trial. JAMA - J. Am. Med. Assoc. 324 :
460–470.
Li, T., Lu, H., and Zhang, W. (2020c). Clinical observation and
management of COVID-19 patients. Emerg. Microbes Infect. 9 :
687–690.
Li, X., and Ma, X. (2017). The role of heparin in sepsis: much more than
just an anticoagulant. Br. J. Haematol. 179 : 389–398.
Li, Y., Xie, Z., Lin, W., Cai, W., Wen, C., Guan, Y., et al. (2020d).
Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients
with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.
Med 0 :
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S.P., Carter, L.J.,
et al. (2020a). Research and Development on Therapeutic Agents and
Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent.
Sci. 6 : 315–331.
Liu, S.T.H., Lin, H.M., Baine, I., Wajnberg, A., Gumprecht, J.P.,
Rahman, F., et al. (2020b). Convalescent plasma treatment of severe
COVID-19: a propensity score–matched control study. Nat. Med.26 : 1708–1713.
Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P.,
Sebastian, T., et al. (2020). Venous and arterial thromboembolic
complications in COVID-19 patients admitted to an academic hospital in
Milan, Italy. Thromb. Res. 191 : 9–14.
Lother, S.A., Abassi, M., Agostinis, A., Bangdiwala, A.S., Cheng, M.P.,
Drobot, G., et al. (2020). Post-exposure prophylaxis or pre-emptive
therapy for severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2): study protocol for a pragmatic randomized-controlled
trial. Can. J. Anesth. 67 : 1201–1211.
Lou, Y., Liu, L., Yao, H., Hu, X., Su, J., Xu, K., et al. (2020).
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and
Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled
Trial. Eur. J. Pharm. Sci. 105631.
Marietta, M., Ageno, W., Artoni, A., Candia, E. De, Gresele, P.,
Marchetti, M., et al. (2020). COVID-19 and haemostasis: A position paper
from Italian Society on Thrombosis and Haemostasis (SISET). Blood
Transfus. 18 : 167–169.
Mascolo, A., Berrino, P.M., Gareri, P., Castagna, A., Capuano, A.,
Manzo, C., et al. (2018). Neuropsychiatric clinical manifestations in
elderly patients treated with hydroxychloroquine: a review article.
Inflammopharmacology 26 : 1141–1149.
Mascolo, A., Scavone, C., Rafaniello, C., Ferrajolo, C., Racagni, G.,
Berrino, L., et al. (2020). Renin-angiotensin system and coronavirus
disease 2019: A narrative review. Front. Cardiovasc. Med. 7 :.
McGonagle, D., O’Donnell, J.S., Sharif, K., Emery, P., and Bridgewood,
C. (2020). Immune mechanisms of pulmonary intravascular coagulopathy in
COVID-19 pneumonia. Lancet Rheumatol. 2 : e437–e445.
Meyer, S. De, Bojkova, D., Cinatl, J., Damme, E. Van, Buyck, C., Loock,
M. Van, et al. (2020). Lack of antiviral activity of darunavir against
SARS-CoV-2. Int. J. Infect. Dis. 97 : 7–10.
Ministère de la Santé (2020). Liste des messages d’alertes.
Mitchell, F. (2020). Vitamin-D and COVID-19: do deficient risk a poorer
outcome? Lancet Diabetes Endocrinol. 8 : 570.
Moderna (2020). Moderna Announces Primary Efficacy Analysis in Phase 3
COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S.
FDA for Emergency Use Authorization | Moderna, Inc.
Molina, J.M., Delaugerre, C., Goff, J. Le, Mela-Lima, B., Ponscarme, D.,
Goldwirt, L., et al. (2020). No evidence of rapid antiviral clearance or
clinical benefit with the combination of hydroxychloroquine and
azithromycin in patients with severe COVID-19 infection. Med. Mal.
Infect. 50 : 384.
monde, Le (2020). Le ministre de la santé déconseille l’ibuprofène
contre le coronavirus.
Montesarchio, V., Parella, R., Iommelli, C., Bianco, A., Manzillo, E.,
Fraganza, F., et al. (2020). Outcomes and biomarker analyses among
patients with COVID-19 treated with interleukin 6 (IL-6) receptor
antagonist sarilumab at a single institution in Italy. J. Immunother.
Cancer 8 : 1089.
Moores, L.K., Tritschler, T., Brosnahan, S., Carrier, M., Collen, J.F.,
Doerschug, K., et al. (2020). Prevention, Diagnosis, and Treatment of
VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and
Expert Panel Report. Chest 158 : 1143–1163.
Nadkarni, G.N., Lala, A., Bagiella, E., Chang, H.L., Moreno, P.R.,
Pujadas, E., et al. (2020). Anticoagulation, Bleeding, Mortality, and
Pathology in Hospitalized Patients With COVID-19. J. Am. Coll. Cardiol.76 : 1815–1826.
Nicolini, L.A., Mikulska, M., Signori, A., Biagio, A. Di, Portunato, F.,
Vena, A., et al. (2020). Reply to: “Antiviral activity and safety of
darunavir/cobicistat for treatment of COVID-19”. Open Forum Infect.
Dis. 7 :.
NIH (2020). Antithrombotic Therapy | COVID-19 Treatment
Guidelines.
Niriella, M.A., Ediriweera, D.S., Silva, A.P. De, Premarathne, R.,
Balasooriya, P., Duminda, K.D., et al. (2020). Hydroxychloroquine for
post-exposure prophylaxis of COVID-19 among naval personnel in Sri
Lanka: Study protocol for a randomized, controlled trial. Trials21 : 748.
Paranjpe, I., Fuster, V., Lala, A., Russak, A.J., Glicksberg, B.S.,
Levin, M.A., et al. (2020). Association of Treatment Dose
Anticoagulation With In-Hospital Survival Among Hospitalized Patients
With COVID-19. J. Am. Coll. Cardiol. 76 : 122–124.
Pasquini, Z., Montalti, R., Temperoni, C., Canovari, B., Mancini, M.,
Tempesta, M., et al. (2020). Effectiveness of remdesivir in patients
with COVID-19 under mechanical ventilation in an Italian ICU. J.
Antimicrob. Chemother. 75 : 3359–3365.
Pavoni, V., Gianesello, L., Pazzi, M., Stera, C., Meconi, T., and
Frigieri, F.C. (2020). Venous thromboembolism and bleeding in critically
ill COVID-19 patients treated with higher than standard low molecular
weight heparin doses and aspirin: A call to action. Thromb. Res.196 : 313–317.
Perrone, F., Piccirillo, M.C., Ascierto, P.A., Salvarani, C., Parrella,
R., Marata, A.M., et al. (2020). Tocilizumab for patients with COVID-19
pneumonia. The single-arm TOCIVID-19 prospective trial. J. Transl. Med.18 :.
Pizzini, A., Aichner, M., Sahanic, S., Böhm, A., Egger, A., Hoermann,
G., et al. (2020). Impact of vitamin d deficiency on covid-19—a
prospective analysis from the covild registry. Nutrients 12 :
1–9.
Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A.,
Lockhart, S., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA
Covid-19 Vaccine. N. Engl. J. Med.
Qian, Z., Travanty, E.A., Oko, L., Edeen, K., Berglund, A., Wang, J., et
al. (2013). Innate immune response of human alveolar type II cells
infected with severe acute respiratory syndrome-coronavirus. Am. J.
Respir. Cell Mol. Biol. 48 : 742–748.
Rajter, J.C., Sherman, M.S., Fatteh, N., Vogel, F., Sacks, J., and
Rajter, J.-J. (2020). Use of Ivermectin Is Associated With Lower
Mortality in Hospitalized Patients With Coronavirus Disease 2019. Chest.
Rattanaumpawan, P., Jirajariyavej, S., Lerdlamyong, K., Palavutitotai,
N., and Saiyarin, J. (2020). Real-world Experience with Favipiravir for
Treatment of COVID-19 in Thailand: Results from a Multi-center
Observational Study. MedRxiv 2020.06.24.20133249.
Regeneron Pharmaceuticals, I. Regeneron’s REGN-COV2 Antibody Cocktail
Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19
Patients | Regeneron Pharmaceuticals Inc.
Rinott, E., Kozer, E., Shapira, Y., Bar-Haim, A., and Youngster, I.
(2020). Ibuprofen use and clinical outcomes in COVID-19 patients. Clin.
Microbiol. Infect. 26 : 1259.e5-1259.e7.
Roche (2020). Roche - Roche provides an update on the phase III COVACTA
trial of Actemra/RoActemra in hospitalised patients with severe COVID-19
associated pneumonia.
Rojas, M., Rodríguez, Y., Monsalve, D.M., Acosta-Ampudia, Y., Camacho,
B., Gallo, J.E., et al. (2020). Convalescent plasma in Covid-19:
Possible mechanisms of action. Autoimmun. Rev. 19 :.
Sadeghi, A., Ali Asgari, A., Norouzi, A., Kheiri, Z., Anushirvani, A.,
Montazeri, M., et al. (2020). Sofosbuvir and daclatasvir compared with
standard of care in the treatment of patients admitted to hospital with
moderate or severe coronavirus infection (COVID-19): a randomized
controlled trial. J. Antimicrob. Chemother. 75 : 3379–3385.
Sanofi (2020a). Sanofi and GSK announce a delay in their adjuvanted
recombinant protein-based COVID-19 vaccine program to improve immune
response in the elderly - Sanofi.
Sanofi (2020b). Sanofi provides update on Kevzara® (sarilumab) Phase 3
trial in severe and critically ill COVID-19 patients outside the U.S. -
Sanofi.
Scavone, C., Brusco, S., Bertini, M., Sportiello, L., Rafaniello, C.,
Zoccoli, A., et al. (2020). Current pharmacological treatments for
COVID-19: What’s next? Br. J. Pharmacol. 177 : 4813–4824.
Scialo, F., Daniele, A., Amato, F., Pastore, L., Matera, M.G., Cazzola,
M., et al. (2020). ACE2: The Major Cell Entry Receptor for SARS-CoV-2.
Lung 198 : 867–877.
Scott, L.J. (2017). Tocilizumab: A Review in Rheumatoid Arthritis. Drugs77 : 1865–1879.
Sheahan, T.P., Sims, A.C., Leist, S.R., Schäfer, A., Won, J., Brown,
A.J., et al. (2020). Comparative therapeutic efficacy of remdesivir and
combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
Nat. Commun. 11 :.
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., et al. (2020).
Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent
Plasma. JAMA - J. Am. Med. Assoc. 323 : 1582–1589.
SHI, C., WANG, C., WANG, H., YANG, C., CAI, F., ZENG, F., et al. (2020).
The potential of low molecular weight heparin to mitigate cytokine storm
in severe COVID-19 patients: a retrospective clinical study. Rappaport
Fac. Med. 2020.03.28.20046144.
Shrestha, D.B., Budhathoki, P., Khadka, S., Shah, P.B., Pokharel, N.,
and Rashmi, P. (2020). Favipiravir versus other antiviral or standard of
care for COVID-19 treatment: a rapid systematic review and
meta-analysis. Virol. J. 17 : 141.
Simonovich, V.A., Burgos Pratx, L.D., Scibona, P., Beruto, M. V.,
Vallone, M.G., Vázquez, C., et al. (2020). A Randomized Trial of
Convalescent Plasma in Covid-19 Severe Pneumonia. N. Engl. J. Med.
Skipper, C.P., Pastick, K.A., Engen, N.W., Bangdiwala, A.S., Abassi, M.,
Lofgren, S.M., et al. (2020). Hydroxychloroquine in Nonhospitalized
Adults With Early COVID-19. Ann. Intern. Med. 173 : 623–631.
Spinner, C.D., Gottlieb, R.L., Criner, G.J., Arribas López, J.R.,
Cattelan, A.M., Soriano Viladomiu, A., et al. (2020). Effect of
Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients
with Moderate COVID-19: A Randomized Clinical Trial. JAMA - J. Am. Med.
Assoc. 324 : 1048–1057.
Sterne, J.A.C., Murthy, S., Diaz, J. V., Slutsky, A.S., Villar, J.,
Angus, D.C., et al. (2020). Association between Administration of
Systemic Corticosteroids and Mortality among Critically Ill Patients
with COVID-19: A Meta-analysis. JAMA - J. Am. Med. Assoc. 324 :
1330–1341.
Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., et al. (2020).
Hydroxychloroquine in patients with mainly mild to moderate coronavirus
disease 2019: Open label, randomised controlled trial. BMJ 369 :.
The Florentine (2020). Covid-19: Monoclonal antibody treatment developed
in Siena.
Tiberghien, P., Lamballerie, X. de, Morel, P., Gallian, P., Lacombe, K.,
and Yazdanpanah, Y. (2020). Collecting and evaluating convalescent
plasma for COVID-19 treatment: why and how? Vox Sang. 115 :
488–494.
Tirupakuzhi Vijayaraghavan, B.K., Jha, V., Rajbhandari, D., Myatra,
S.N., John, O., Ghosh, A., et al. (2020). Hydroxychloroquine plus
personal protective equipment versus standard personal protective
equipment alone for the prevention of COVID-19 infections among
frontline healthcare workers: The HydrOxychloroquine Prophylaxis
Evaluation(HOPE) trial: A structured summary of a study protocol for a
randomized controlled trial. Trials 21 : 754.
Tleyjeh, I.M., Kashour, Z., Damlaj, M., Riaz, M., Tlayjeh, H., Altannir,
M., et al. (2020). Efficacy and safety of tocilizumab in COVID-19
patients: A living systematic review and meta-analysis. Clin. Microbiol.
Infect.
Tomazini, B.M., Maia, I.S., Cavalcanti, A.B., Berwanger, O., Rosa, R.G.,
Veiga, V.C., et al. (2020). Effect of Dexamethasone on Days Alive and
Ventilator-Free in Patients with Moderate or Severe Acute Respiratory
Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.
JAMA - J. Am. Med. Assoc. 324 : 1307–1316.
University of Oxford (2020a). Aspirin to be investigated as a possible
treatment for COVID-19 in the RECOVERY trial — RECOVERY Trial.
University of Oxford (2020b). Welcome — RECOVERY Trial.
US Food and Drug Administration (2020a). FDA cautions against use of
hydroxychloroquine or chloroquine for COVID-19 outside of the hospital
setting or a clinical trial due to risk of heart rhythm problems
| FDA.
US Food and Drug Administration (2020b). Recommendations for
Investigational COVID-19 Convalescent Plasma | FDA.
Valle, D.M. Del, Kim-Schulze, S., Huang, H.H., Beckmann, N.D.,
Nirenberg, S., Wang, B., et al. (2020). An inflammatory cytokine
signature predicts COVID-19 severity and survival. Nat. Med. 26 :
1636–1643.
Voysey, M., Ann, S., Clemens, C., Madhi, S.A., Weckx, L.Y., Folegatti,
P.M., et al. (2020). Articles Safety and efficacy of the ChAdOx1 nCoV-19
vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four
randomised controlled trials in Brazil, South Africa, and the UK. Lancet0 :
Wang, J., Nikrad, M.P., Phang, T., Gao, B., Alford, T., Ito, Y., et al.
(2011). Innate immune response to influenza A virus in differentiated
human alveolar type II cells. Am. J. Respir. Cell Mol. Biol. 45 :
582–591.
Wang, M., Wu, T., Zuo, Z., You, Y., Yang, X., Pan, L., et al. (2020a).
Evaluation of current medical approaches for COVID-19: a systematic
review and meta-analysis. BMJ Support. Palliat. Care
bmjspcare-2020-002554.
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., et al. (2020b).
Remdesivir in adults with severe COVID-19: a randomised, double-blind,
placebo-controlled, multicentre trial. Lancet 395 : 1569–1578.
WATANABE, S., CHAN, M., SUZUKI, W., and Nikkei staff writers (2020).
China says Japan-developed drug Avigan works against coronavirus -
Nikkei Asia.
Wit, E. de, Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas,
T., et al. (2020). Prophylactic and therapeutic remdesivir (GS-5734)
treatment in the rhesus macaque model of MERS-CoV infection. Proc. Natl.
Acad. Sci. U. S. A. 117 : 6771–6776.
World Health Organization WHO recommends against the use of remdesivir
in COVID-19 patients.
World Health Organization (2020a). Clinical management of COVID-19.
World Health Organization (2020b). Draft landscape of COVID-19 candidate
vaccines.
World Health Organization (2020c). Solidarity clinical trial for
COVID-19 treatments .
World Health Organization (2020d). WHO/Europe | Antimicrobial
resistance - Preventing the COVID-19 pandemic from causing an antibiotic
resistance catastrophe.
World Health Organization (2020e). WHO discontinues hydroxychloroquine
and lopinavir/ritonavir treatment arms for COVID-19.
Worldometer (2020). Coronavirus Update (Live): 60,272,757 Cases and
1,418,260 Deaths from COVID-19 Virus Pandemic - Worldometer.
Wu, X., Yu, K., Wang, Y., Xu, W., Ma, H., Hou, Y., et al. (2020).
Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019:
A Pilot Randomized Controlled Trial. Engineering.
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., et al. (2020).
Effective treatment of severe COVID-19 patients with tocilizumab. Proc.
Natl. Acad. Sci. U. S. A. 117 : 10970–10975.
Zemb, P., Bergman, P., Camargo, C.A., Cavalier, E., Cormier, C.,
Courbebaisse, M., et al. (2020). Vitamin D deficiency and the COVID-19
pandemic. J. Glob. Antimicrob. Resist. 22 : 133–134.
Zhang, B., Liu, S., Tan, T., Huang, W., Dong, Y., Chen, L., et al.
(2020a). Treatment With Convalescent Plasma for Critically Ill Patients
With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest158 : e9–e13.
Zhang, X., Zhang, Y., Qiao, W., Zhang, J., and Qi, Z. (2020b).
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from
entering target cells and control cytokine storm induced by COVID-19.
Int. Immunopharmacol. 86 :.
Zhang, Z., Wang, S., Tu, X., Peng, X., Huang, Y., Wang, L., et al.
(2020c). A comparative study on the time to achieve negative nucleic
acid testing and hospital stays between danoprevir and
lopinavir/ritonavir in the treatment of patients with COVID-19. J. Med.
Virol. 92 : 2631–2636.
Zhu, Z., Lu, Z., Xu, T., Chen, C., Yang, G., Zha, T., et al. (2020).
Arbidol monotherapy is superior to lopinavir/ritonavir in treating
COVID-19. J. Infect. 81 : e21–e23.